Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

• Egile Nagusiak: Lu-Qi Cao (Egilea), Haidong Sun (Egilea), Yuhao Xie (Egilea), Harsh Patel (Egilea), Letao Bo (Egilea), Hanli Lin (Egilea), Zhe-Sheng Chen (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Breast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor and human epidermal growth factor receptor 2 (HER2) levels, among which a significant subtype known as HR+/HER2-breast cancer that has spurred numerous research. The prevalence of breast cancer and bre...